U.S. markets closed
  • S&P 500

    4,185.47
    +15.05 (+0.36%)
     
  • Dow 30

    34,200.67
    +164.67 (+0.48%)
     
  • Nasdaq

    14,052.34
    +13.54 (+0.10%)
     
  • Russell 2000

    2,262.67
    +5.60 (+0.25%)
     
  • Crude Oil

    63.07
    -0.06 (-0.10%)
     
  • Gold

    1,777.30
    -2.90 (-0.16%)
     
  • Silver

    26.04
    -0.06 (-0.25%)
     
  • EUR/USD

    1.1983
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    1.5730
    +0.0430 (+2.81%)
     
  • GBP/USD

    1.3826
    +0.0042 (+0.30%)
     
  • USD/JPY

    108.7800
    +0.0640 (+0.06%)
     
  • BTC-USD

    56,127.00
    -5,282.54 (-8.60%)
     
  • CMC Crypto 200

    1,398.97
    +7.26 (+0.52%)
     
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • Nikkei 225

    29,683.37
    +40.67 (+0.14%)
     

Matinas BioPharma (MTNB) Looks Good: Stock Adds 8.6% in Session

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Matinas BioPharma Holdings, Inc. MTNB was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of 76-89 cents per share in the past one-month time frame.

The company has seen one positive estimate revision in the past month, while its Zacks Consensus Estimate for the current quarter has also moved higher in the same time frame, suggesting that more solid trading could be ahead for Matinas BioPharma. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Matinas BioPharma currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.

Matinas BioPharma Holdings, Inc. Price

Matinas Biopharma Holdings, Inc. Price
Matinas Biopharma Holdings, Inc. Price

Matinas BioPharma Holdings, Inc. price | Matinas BioPharma Holdings, Inc. Quote

A better-ranked stock in the Medical – Drugs industry is Ironwood Pharmaceuticals, Inc. IRWD, which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot stocks we're targeting >>
 


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Ironwood Pharmaceuticals, Inc. (IRWD) : Free Stock Analysis Report
 
Matinas Biopharma Holdings, Inc. (MTNB) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research